Wuxi Biologics (2269 HK) is looking to raise US$1.3bn in its primary placement to fund acquisitions and expand capacity. This is the company's 13th placement since it listed in June 2017.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.